CLARIO AGE TRIAL

Promotes discrimination based on race, sex, religion, nationality, disability, sexual orientation, or age Ģ.2.6. Promotes sexually explicit materials Ģ.2.4. Violates Affiliate Marketing Guideline Ģ.2.2. We may refuse your application and/or suspend or terminate and ban you from participating in the Program if we find out, or have reasonable assumptions that you or your website is unsuitable for our Program, including but not limited to if you or it:Ģ.2.1. We may reject your application or terminate this Agreement at any time at our sole discretion.Ģ.2. The fact that we approve your application does not imply that we may not re-evaluate your application.

We will review the application and will approve or reject it. To begin the enrollment process, you need to complete and submit the online application at the. By entering this Agreement you hereby represent and warrant that you are at least 18 years old or other legal age and have full, lawful power and authority to enter into and to carry out the terms of this Agreement.Ģ.1. By submitting your application, you agree to be bound by the terms of this Agreement and Marketing Guidance (attached at the bottom of the Agreement). Please note that throughout this Agreement, “Clario”, 'we,' 'us,' and 'our' refer to Clario, and “Affiliate”, 'you', 'your' and 'yours' refer to the Affiliate.ġ.2. This Affiliate Agreement (hereinafter - “Agreement”) together with IO and Affiliate Marketing Guideline (hereinafter - “Marketing Guideline”) contain the complete terms and conditions that apply to you becoming an Affiliate (hereinafter - “Affiliate”) in MacKeeper Affiliate Program (hereinafter - “Program”). With firmly-rooted study teams on the ground in China and the US, XingImaging works in collaboration with biotech and pharmaceutical companies for the testing and advancement of therapeutics through brain imaging.įor more information, please visit and or follow us on LinkedIn and Twitter.1.1. Established in January 2018 with that goal, XingImaging is a recognized US based biomarker imaging company leading radiopharmaceutical imaging trials in China. XingImaging fills the distinctive clinical research role of a radiopharmaceutical production and PET acquisition CRO in the People's Republic of China. With 30 facilities in nine countries across North America, Europe and Asia Pacific, Clario's global team of science, technology and operational experts has been delivering the richest clinical evidence for nearly 50 years.

CLARIO AGE TRIAL

Through Trial Anywhere™, Clario has mastered the ability to generate rich evidence across all trial models: decentralized, hybrid and site-based clinical trials. Through experience gained from over 19,000 clinical trials delivered in support of 870 regulatory approvals, Clario fuses scientific expertise and global scale into the broadest endpoint technology platform to enable pharmaceutical, biotech and medical device partners to transform lives. 'Our partnership enables patients in China to participate in clinical trials testing novel neurodegenerative disease therapeutics.'Ĭlario delivers the leading endpoint technology solutions for clinical trials. 'XingImaging is proud to be working with Clario in providing PET imaging multi-center clinical trials,' says Gilles Tamagnan, CEO XingImaging, LLC. 'Our continued partnership with XingImaging is advancing therapeutics in APAC.' 'Broadening our scope of clinical trials to further support drug development in neuroscience presents a unique opportunity for both patients and clinical researchers,' says Joyce Suhy, PhD, SVP Medical Imaging at Clario. The new expanded offering leverages the joint resources and neuroscience experts of Clario and XingImaging to expedite the startup of clinical trials and drug discovery in China, including amyloid, tau, and other targets. A dedicated team of neuroscientists and project managers have led multiple trials in China to date. PET imaging has supported novel studies for Alzheimer's disease (AD) and other neurodegenerative diseases. 11, 2022 /PRNewswire/ - Clario, a technology company that delivers the leading endpoint technology solutions for clinical trials, and XingImaging, a radiopharmaceutical production and positron emission tomography (PET) acquisition company, have expanded their partnership to deliver PET imaging clinical trials for testing novel therapeutics in China.Ĭlario, formerly ERT and Bioclinica, and XingImaging joined forces in 2018 to support multi-center clinical trials requiring PET for eligibility and drug efficacy evaluation.

Clario age